Duopharma Biotech Berhad has appointed Wan Amir-Jeffery Wan Abdul Majid as Group Chief Executive Officer of Duopharma Biotech Berhad effective 1 October 2025. Prior to this appointment, Wan Amir-Jeffery, was Duopharma Biotech’s Chief Executive Officer – Group Operations.
Kuala Lumpur, August 28, 2025 — Duopharma Biotech Berhad has appointed Wan Amir-Jeffery Wan Abdul Majid as Group Chief Executive Officer of Duopharma Biotech Berhad effective 1 October 2025.
Prior to this appointment, Wan Amir-Jeffery was Duopharma Biotech’s Chief Executive Officer – Group Operations.
Datin Paduka Kartini Hj Abdul Manaf, Chairman of Duopharma Biotech said, “I congratulate Encik Wan Amir-Jeffery on his appointment as the Group Chief Executive Officer of Duopharma Biotech. In his tenure of service since joining us, he has contributed immensely to the Company strategically and operationally. I am confident that Duopharma Biotech will continue its healthy growth trajectory, strengthening its position as a leading pharmaceutical company in Malaysia.”
Wan Amir-Jeffery joined Duopharma Biotech in September 2016 as Chief Strategy Officer.
- In 2018, he was promoted to Chief Operating Officer.
- Two years later, in 2020, he assumed the role of Chief Commercial Officer.
- In 2022, he was elevated to Chief Executive Officer – Commercial.
- After two years, in 2024, he was appointed Chief Executive Officer – Group Operations.
He holds a Bachelor of Business Administration (International Trade) degree from the University of Central Arkansas and an alumnus of the Senior Management Development Program of Harvard Business School.
Wan Amir-Jeffery is currently a Vice-President of the Malaysian Organisation of Pharmaceutical Industries (MOPI) for the 2025–2027 term.
| This is a press statement issued by Duopharma Biotech Group. It has been edited for clarity. |
